Reducing the Risk of Tuberculosis Reactivation when Administering Everolimus for a Pancreatic Neuroendocrine Tumor: A Case Report Abstract #647

Introduction: Everolimus can potentially reactivate tuberculosis (TB) through immunosuppression. This was recently reported to have occurred in a kidney transplant recipient. To date, no clear strategy has been developed for reducing the risk of TB reactivation during everolimus treatment.
Aim(s): We report a case of a pancreatic neuroendocrine tumor (pNET) in a patient with a latent tuberculosis infection (LTBI).
Materials and methods: A 70-year-old woman was diagnosed as having pancreatic cancer and liver metastases. She received chemotherapy with S-1, followed by transcatheter arterial infusion chemotherapy of the whole liver using 5-fluorouracil, but the liver metastases progressed. A needle biopsy of the liver tumor confirmed the diagnosis of NET G2. The Ki-67 labeling index was 6%. The serum gastrin level was 1370 pg/mL (normal, 37–172 pg/mL). Treatment with octreotide followed by octreotide LAR was started. However, after 10 months, positron emission tomography-computed tomography (CT) showed tumor metastasis to the sacral region and chest CT showed small nodules in the lung. Before the administration of everolimus, LTBI was confirmed by the QuantiFERON-TB Gold test, and isoniazid was therefore started simultaneously with everolimus to reduce the risk of TB reactivation.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: MD Takeshi Tamura
Keywords: everolimus, NET, LTBI

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD PhD Antonio Viudez
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2924 Everolimus in Patients with Advanced Neuroendocrine Neoplasia: A Real-World Study and Analysis of Long Responders
Introduction: Everolimus is a valid therapeutic option for neuroendocrine tumors (NETs); however, data regarding the long responsders in a real-world setting, outside regulatory trials, are scanty.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Maria Rinzivillo
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...